Sequential hepatic arterial infusion chemotherapy with cisplatin followed by sorafenib versus sorafenib alone in advanced hepatocellular carcinoma
Phase 2
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000006147
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1) Esophageal and/or gastric varices which has high risk of bleeding and clinically significant gastro- intestinal bleeding. 2) Clinically uncontrolled ascites or pleural effusion. 3) Existing of hepatic encephalopathy 4) Serious hypertension. 5) Preexisting of history with severe coronary or cerebral artery diseases. 6) Renal failure. 7) Patients who are pregnant, suspected to be pregnant, or wish to become pregnant. 8) Risk of allergic reactions to the study drugs. 9) Active duplicative cancer 10) Previous malignancy 11) Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year survival
- Secondary Outcome Measures
Name Time Method overall survival, 2-year survival, time to progression, response rate, safety